Research
Early Response to MASH Drug Linked to Resolution, Fibrosis Improvement
The Brief
- In patients treated with resmetirom (Rezdiffra), early responses in blood and imaging biomarkers were associated with resolution of MASH.
- The same early biomarker responses were also associated with fibrosis improvement.
- The report comes from MedPage Today's coverage of an AASLD meeting; the full study details are not in the provided excerpt.
Why it matters
If early blood and imaging biomarker changes track with MASH resolution and fibrosis improvement, they could help clinicians and researchers assess treatment response sooner than waiting for later outcomes.
Who’s affected
- hepatologists and clinicians treating MASH
- researchers developing MASH treatments and biomarkers
- patients with MASH
- #mash
- #resmetirom
- #liver fibrosis
- #biomarkers
- #hepatology
(MedPage Today) -- In patients treated with resmetirom (Rezdiffra), early responses in blood and imaging biomarkers were associated with resolution of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis improvement, according to...